Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Exelixis total assets
Total assets on the balance sheet at the end of each period.
Exelixis's total assets was $2.51B at Oct 2, 2026. For fiscal 2025 it was $2.84B, down 3.5% from the year before. Over ten years it grew 23.9% a year on average. The highest annual figure on record is $3.07B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.84B | -3.5% |
| FY2024 | Jan 3, 2025 | $2.95B | +0.2% |
| FY2023 | Dec 29, 2023 | $2.94B | -4.2% |
| FY2022 | Dec 30, 2022 | $3.07B | +17.4% |
| FY2021 | Dec 31, 2021 | $2.62B | +22.4% |
| FY2020 | Jan 1, 2021 | $2.14B | +13.3% |
| FY2019 | Jan 3, 2020 | $1.89B | +32.6% |
| FY2018 | Dec 28, 2018 | $1.42B | +117.0% |
| FY2017 | Dec 29, 2017 | $655.29M | +10.0% |
| FY2016 | Dec 31, 2016 | $595.74M | +79.3% |
| FY2015 | Dec 31, 2015 | $332.34M | +2.8% |
| FY2014 | Dec 31, 2014 | $323.27M | -35.8% |
| FY2013 | Dec 31, 2013 | $503.29M | -30.2% |
| FY2012 | Dec 31, 2012 | $721.10M | +83.4% |
| FY2011 | Dec 31, 2011 | $393.26M | +9.0% |
| FY2010 | Dec 31, 2010 | $360.79M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $2.51B | -11.0% |
| Q2 FY2026 | Jul 3, 2026 | $2.49B | -6.9% |
| Q1 FY2026 | Apr 3, 2026 | $2.59B | -8.6% |
| Q4 FY2025 | Jan 2, 2026 | $2.84B | -3.5% |
| Q3 FY2025 | Oct 3, 2025 | $2.82B | -4.6% |
| Q2 FY2025 | Jul 4, 2025 | $2.68B | -3.4% |
| Q1 FY2025 | Apr 4, 2025 | $2.84B | +1.2% |
| Q4 FY2024 | Jan 3, 2025 | $2.95B | +0.2% |
| Q3 FY2024 | Sep 27, 2024 | $2.96B | -0.6% |
| Q2 FY2024 | Jun 28, 2024 | $2.77B | -11.8% |
| Q1 FY2024 | Mar 29, 2024 | $2.80B | -10.8% |
| Q4 FY2023 | Dec 29, 2023 | $2.94B | -4.2% |
| Q3 FY2023 | Sep 29, 2023 | $2.98B | +0.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.14B | +9.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.14B | +18.4% |
| Q4 FY2022 | Dec 30, 2022 | $3.07B | +17.4% |
| Q3 FY2022 | Sep 30, 2022 | $2.96B | +21.0% |
| Q2 FY2022 | Jul 1, 2022 | $2.88B | +21.7% |
| Q1 FY2022 | Apr 1, 2022 | $2.65B | +21.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.62B | +22.4% |
| Q3 FY2021 | Oct 1, 2021 | $2.45B | +15.9% |
| Q2 FY2021 | Jul 2, 2021 | $2.37B | +15.7% |
| Q1 FY2021 | Apr 2, 2021 | $2.19B | +12.0% |
| Q4 FY2020 | Jan 1, 2021 | $2.14B | +13.3% |
| Q3 FY2020 | Oct 2, 2020 | $2.11B | +18.3% |
| Q2 FY2020 | Jul 3, 2020 | $2.05B | +24.6% |
| Q1 FY2020 | Apr 3, 2020 | $1.96B | +26.8% |
| Q4 FY2019 | Jan 3, 2020 | $1.89B | +32.6% |
| Q3 FY2019 | Sep 27, 2019 | $1.78B | +74.2% |
| Q2 FY2019 | Jun 28, 2019 | $1.64B | +80.3% |
| Q1 FY2019 | Mar 29, 2019 | $1.54B | +99.0% |
| Q4 FY2018 | Dec 28, 2018 | $1.42B | +117.0% |
| Q3 FY2018 | Sep 28, 2018 | $1.02B | +68.0% |
| Q2 FY2018 | Jun 29, 2018 | $911.16M | +76.4% |
| Q1 FY2018 | Mar 30, 2018 | $774.92M | +32.0% |
| Q4 FY2017 | Dec 29, 2017 | $655.29M | +10.0% |
| Q3 FY2017 | Sep 30, 2017 | $609.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $516.53M | – |
| Q1 FY2017 | Mar 31, 2017 | $586.98M | – |
| Q4 FY2016 | Dec 31, 2016 | $595.74M | – |
See a number that looks wrong?